{
  "source": "PA-Notification-Welireg.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1370-5\nProgram Prior Authorization/Notification\nMedication Welireg™ (belzutifan)\nP&T Approval Date 10/2021, 10/2022, 10/2023, 2/2024, 7/2024\nEffective Date 10/1/2024\n1. Background:\nWelireg™ (belzutifan) is a hypoxia-inducible factor inhibitor indicated for treatment of adult\npatients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell\ncarcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic\nneuroendocrine tumors (pNET), not requiring immediate surgery. Welireg is also indicated for\nthe treatment of adult patients with advanced renal cell carcinoma (RCC) following a\nprogrammed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a\nvascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Welireg will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Von Hippel-Lindau (VHL) Disease\n1. Initial Authorization\na. Welireg will be approved based on all the following criteria:\n(1) Diagnosis of von Hippel-Lindau (VHL) disease\n-AND-\n(2) Patient requires therapy for one of the following:\n© 2024 UnitedHealthcare Services, Inc.\n1\n(a) Renal cell carcinoma (RCC)\n(b) Central nervous system (CNS) hemangioblastoma\n(c) Pancreatic neuroendocrine tumor (pNET)\n-AND-\n(3) Patient does not require immediate ",
    "tedHealthcare Services, Inc.\n1\n(a) Renal cell carcinoma (RCC)\n(b) Central nervous system (CNS) hemangioblastoma\n(c) Pancreatic neuroendocrine tumor (pNET)\n-AND-\n(3) Patient does not require immediate surgery\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Welireg will be approved based on the following criterion:\n(1) Patient does not show evidence of disease progression while on Welireg.\nAuthorization will be issued for 12 months.\nC. Advanced Renal Cell Carcinoma\n1. Initial Authorization\na. Welireg will be approved based on all the following criteria:\n(1) Diagnosis of advanced renal cell carcinoma (RCC)\n-AND-\n(2) Disease has progressed after treatment with both of the following:\n(a) Programmed death receptor 1 (PD-1) or programmed death ligand 1 (PD-\nL1) checkpoint inhibitor [e.g.,Keytruda (pembrolizumab), Opdivo\n(nivolumab)]\n-AND-\n(b) Vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI)\n[e.g., Cabometyx (cabozantinib), Inlyta (axitinib), Lenvima (lenvatinitb)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Welireg will be approved based on the following criterion:\n(1) Patient does not show evidence of disease progression while on Welireg.\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n2\nD. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or clai",
    "l Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Welireg [package insert]. Rathway, NJ: Merck & Co., Inc.; December 2023.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nwww.nccn.org. Accessed May 31, 2024.\nProgram Prior Authorization/Notification – Welireg (belzutifan)\nChange Control\n10/2021 New program\n10/2022 Annual review with no changes to clinical coverage criteria. Added\nstate mandate footnote. Updated references.\n10/2023 Annual review with no changes to coverage criteria. Updated\nreferences.\n2/2024 Added criteria for advanced renal cell carcinoma. Updated background\nand references.\n7/2024 Updated examples of PD-L1 checkpoint inhibitors and VEGF-TKIs\nwithin advanced RCC criteria.\n© 2024 UnitedHealthcare Services, Inc.\n3"
  ]
}